Reuters exclusively reports South Korea offers to produce mRNA vaccines

Last Updated on 10/07/2021 by


Reuters reported exclusively that South Korea is in talks with mRNA vaccine makers, including Pfizer and Moderna, to produce COVID-19 shots in the country and is ready to offer the capacity to make up to 1 billion doses immediately. The plan, if agreed, would help ease tight global supply of COVID-19 vaccines, particularly in Asia, and put South Korea a step closer to its ambition to become a major vaccine manufacturing center. According to a Reuters source, local vaccine makers, which have the capacity to produce mRNA vaccines immediately, include Hanmi Pharmaceuticals Co LtdĀ and Quratis Co Ltd.

Market Impact

Shares in Hanmi rose nearly 7% after the Reuters report, and its top shareholder Hanmi Science jumped 10.3%.

Article Tags

Topics of Interest: Health

Type: Reuters Best

Sectors: Pharmaceuticals & Healthcare

Regions: Asia

Countries: South Korea

Win Types: Exclusivity

Story Types: Exclusive / Scoop

Media Types: Text

Customer Impact: Important Regional Story

Source link